bone erosion

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.

Eleutheroside E has anti-inflammatory effects by inhibiting NF-κB activities. Eleutheroside E significantly decreases the inflammatory cell infiltration, pannus formation, cartilage damage, bone erosion of CIA mice, the generation of TNF-α and IL-6, the m

ELP-004 is a TRPC channel inhibitor that blocks Ca2+ entry mediated by TRPC channels. It serves as an osteoclast inhibitor by preventing osteoclast differentiation. ELP-004 also hinders basal Ca2+ levels and the associated translocation of NFATc1 in inflammatory osteoclastogenesis. Additionally, it reduces bone erosion in mouse models of rheumatoid arthritis.

Praeruptorin A ((+)-Praeruptorin A) has the potential to inhibit migration/fusion of preosteoclasts in vitro and bone erosion in vivo by targeting calmodulin and inhibiting the Ca(2+)/calmodulin-CaMKIV-CREB-NFATc1 and/or Ca(2+)/calmodulin-calcineurin-NFATc1 signaling axis.

1. (±)-Praeruptorin A could exhibit its anti-osteoclastogenic activity by inhibiting p38 Akt-c-Fos-NFATc1 signaling and PLCγ-independent Ca(2+) oscillation 2. Praeruptorin A has the potential to inhibit migration fusion of preosteoclasts in vitro and bone erosion in vivo by targeting calmodulin and inhibiting the Ca(2+) calmodulin-CaMKIV-CREB-NFATc1 and or Ca(2+) calmodulin-calcineurin-NFATc1 signaling axis. 3. Praeruptorin A and praeruptorin C can significantly upregulate multidrug resistance-associated protein 2 expression via the constitutive androstane receptor-mediated pathway in vitro, and this should be taken as an herb-drug interaction.

Osteostatin (human), a fragment derived from parathyroid hormone-related protein (PTHrP) 107-139, effectively promotes bone repair in animal models with bone defects and inhibits bone erosion in cases of inflammatory arthritis [1].

Osteostatin, derived from parathyroid hormone-related protein (PTHrP) 107-111, has demonstrated properties conducive to bone repair in animal models presenting with bone defects and exhibits efficacy in mitigating bone erosion associated with inflammatory arthritis. Additionally, it possesses the capacity to inhibit both collagen-induced arthritis and direct osteoclastic bone resorption, marking its potential utility in inflammation and immunology research [1] [2] [3] [4].

Body Protection Compound 157 (BPC 157) is a pentadecapeptide derived from BPC, identified in gastric juice, exhibiting diverse biological activities. At 2 µg/ml, BPC 157 enhances primary rat tendon fibroblast cell migration and F-actin formation. Furthermore, doses of 0.01 and 10 µg/kg, intraperitoneally (i.p.), mitigate paw swelling, bone erosion, and mononuclear cell infiltration in the joints of rats with rheumatoid arthritis induced by complete Freund's adjuvant (CFA). It also diminishes gastric ulcer size in rats caused by indomethacin, aspirin, or diclofenac at these doses. Additionally, BPC 157 reduces catalepsy duration and tremor severity in a mouse model of Parkinson's disease triggered by MPTP.